NCT03382938 is a NA clinical trial of Dexmedetomidine in Postoperative Pain, sponsored by Attikon Hospital.

Who is sponsoring NCT03382938?

NCT03382938 is sponsored by Attikon Hospital.

What drugs are being tested in NCT03382938?

Interventions in NCT03382938: Dexmedetomidine, Ropivacaine, Dexmedetomidine - Ropivacaine, 0,9% saline.

What condition does NCT03382938 study?

NCT03382938 studies Postoperative Pain.

Is NCT03382938 still recruiting?

NCT03382938 is currently recruiting now. Last updated 19 March 2025.

Last reviewed 2025-03-19 · How we verify

NCT03382938

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine Wound Infiltration in Cesarean Section

Recruiting now NA Last updated 19 March 2025

What this trial tests

NA trial testing Dexmedetomidine in Postoperative Pain in 100 participants. Currently enrolling.

Timeline

23 August 2019

Primary endpoint
20 December 2025

20 November 2026

Quick facts

Lead sponsor	Attikon Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	100
Start date	23 August 2019
Primary completion	20 December 2025
Estimated completion	20 November 2026
Sites	1 location across Greece

Drugs / interventions tested

Dexmedetomidine (dexmedetomidine) — full drug profile →
Ropivacaine (ROPIVACAINE) — full drug profile →
Dexmedetomidine - Ropivacaine — full drug profile →
0,9% saline — full drug profile →

Conditions studied

Postoperative Pain — all drugs for Postoperative Pain →

Sponsor

Attikon Hospital

Who can join

Adults 18 to 40, female only, with Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effects of four different wound infiltration protocols in cesarean section will be investigated on parturient' pain intensity, PCA morphine consumption given, side effects and parturient' overall satisfaction. One group will receive for wound infiltration dexmedetomidine, the second ropivacaine, the third dexmedetomidine combined with ropivacaine, while the last one will receive normal saline (placebo group).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07306702 — Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients · Phase 4 · withdrawn
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting

Other Attikon Hospital trials

Trials by the same sponsor.

NCT07425457 — Cryoneurolysis Prior to Total Knee Arthroplasty (CRYO-TKA Trial) · NA · recruiting
NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
NCT06810700 — The Association Between Time in Range With Markers of Endothelial and Cardiovascular Function · not yet recruiting
NCT06978387 — The Association Between Glycemic Metrics and Cardiovascular Markers in Patients With Type 1 Diabetes. · active not recruiting
NCT06749613 — Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03382938 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Attikon Hospital
Last refreshed: 19 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03382938.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing